Thursday, February 22, 2018
Dedicated to creating technologies and tools to improve peoples' lives, ATUM today announced a patent licensing agreement giving Just Biotherapeutics access to the company’s Leap-In cell line development tools.
“We love everything about Just’s mission, and we are delighted that our Leap-In technology will be used to help democratize access to life-changing, life-saving drugs,” said Jeremy Minshull, PhD, CEO of ATUM.
Just creates new cost-effective discovery and manufacturing platforms to make biologic medicines accessible to global markets. The Leap-In system enables researchers to quickly and efficiently produce stable, high producing cell lines, therefore moving promising therapeutics to the market faster and less expensively than other methods.
“We are pleased to be working with innovative technology solutions like those provided by ATUM,” said Jim Thomas, CEO of Just. “The Leap-In Transposase system fits well with our biologics platform, helping us achieve higher expression levels more rapidly than conventional cell line development methods.”
Just was granted the R&D and commercial license after previewing the technology via an evaluation license from ATUM.
